scinapse is loading now...
Ana María Guevara
4Publications
2H-index
60Citations
Publications 4
Newest
Published on Jan 2, 2019in Human Vaccines & Immunotherapeutics 2.23
Ana María Guevara2
Estimated H-index: 2
,
Eugenio Suarez4
Estimated H-index: 4
(University of Chile)
+ 7 AuthorsAlain Luxembourg20
Estimated H-index: 20
(Merck & Co.)
Source Cite
Published on Dec 1, 2017in Papillomavirus Research
Ángela María Ruiz Sternberg5
Estimated H-index: 5
(Del Rosario University),
Edson D. Moreira9
Estimated H-index: 9
(Obras Sociais Irmã Dulce)
+ 21 AuthorsAlejandro Victoria1
Estimated H-index: 1
Moreira Junior, Edson Duarte. Associacao Obras Sociais Irma Dulce / Fundacao Oswaldo Cruz. Centro de Pesquisas Goncalo Moniz. Salvador, BA, Brasil. a Clinical Research Group, Universidad del Rosario, Bogota, Colombia b Associacao Obras Sociais Irma Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia, Brazil c Foundation Clinical Research Center CIC, Medellin, Colombia d Research Center on Public Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico e Via Lib...
1 Citations Source Cite
Published on Sep 1, 2017in Vaccine 3.29
Ana María Guevara2
Estimated H-index: 2
,
Robinson Cabello1
Estimated H-index: 1
+ 7 AuthorsAlain Luxembourg20
Estimated H-index: 20
(Merck & Co.)
Abstract Background The 9-valent HPV (9vHPV) vaccine was developed to prevent infection and disease related to 9 HPV types (HPV6/11/16/18/31/33/45/52/58) which cause approximately 90% of cervical cancers, HPV-related vulvar, vaginal and anal cancers, and genital warts worldwide. In a pivotal efficacy study, the 9vHPV vaccine prevented infection and disease due to the 9 vaccine types. Duration of protection remains to be determined. Vaccines that induce long-term protection are generally characte...
6 Citations Source Cite
Published on Nov 1, 2015in Vaccine 3.29
Xavier Castellsagué3
Estimated H-index: 3
,
Anna R. Giuliano65
Estimated H-index: 65
+ 8 AuthorsSusan S. Kaplan5
Estimated H-index: 5
(Merck & Co.)
Abstract Objectives This study was designed to evaluate the immunogenicity and tolerability of a prophylactic 9-valent HPV (types 6/11/16/18/31/33/45/52/58) VLP (9vHPV) vaccine in young men 16–26 years of age in comparison to young women 16–26 years of age (the population that was used to establish 9vHPV vaccine efficacy). Safety and immunogenicity data from this study will be used to bridge 9vHPV vaccine efficacy findings in 16–26 year old women to 16–26 year old men. Methods This study enrolle...
53 Citations Source Cite
1